As India’s cancer burden continues to rise — with an estimated 1.87 million new cases likely to be diagnosed in 2026, placing roughly one in nine Indians at lifetime risk — a rapidly emerging scientific frontier called “space oncology” is generating serious interest among researchers and regulators worldwide. This interdisciplinary field investigates how microgravity and cosmic radiation affect cancer cell behaviour, tumour progression, and drug development, using the International Space Station (ISS) and other orbital platforms as natural laboratories for cancer biology research that would be difficult or impossible to replicate under Earth’s gravity.
The significance of this emerging field extends beyond scientific curiosity. In 2025, the United States Food and Drug Administration (FDA) approved a subcutaneous form of the immunotherapy drug pembrolizumab, developed through protein crystal growth research conducted aboard the ISS by NASA, targeting the ADAR1 gene. Similarly, rebecsinib became the first space-tested cancer drug to enter clinical trials after receiving FDA “Investigational New Drug” status, following successful ISS-linked testing. These are not isolated experiments but signals of an accelerating trend where space-based platforms are becoming legitimate infrastructure for pharmaceutical innovation.
💡 Get AI-powered exam prep on your phone!
For UPSC and SSC aspirants, this topic combines science and technology with public health policy, India’s space economy ambitions through ISRO, and global regulatory innovation — making it a rich, multidimensional subject for both objective and descriptive examination formats.
Background and Context
Cancer is a group of diseases in which abnormal cells grow uncontrollably, invading nearby tissue and often metastasising to distant organs. India spends approximately ₹3,400 crore annually on direct and indirect cancer-related medical costs, a figure that excludes income loss, debt, asset depletion, and caregiver burden — making cancer one of the most economically disruptive illnesses for Indian families. Space oncology emerged from the recognition that Earth-based laboratory conditions, dominated by gravitational sedimentation, cannot fully replicate certain biological processes relevant to cancer progression and drug formulation.
Five Important Key Points
- India is expected to diagnose an estimated 1.87 million new cancer cases in 2026, with roughly one in nine Indians facing a lifetime risk of developing cancer, underscoring the urgency of new treatment research avenues like space oncology.
- Microgravity research has shown that breast cancer cells shift toward a less malignant, less aggressive phenotype in space due to disrupted focal adhesion formation, while gastrointestinal and colorectal cancer cells become more aggressive and more sensitive to chemotherapy drugs like doxorubicin, revealing cancer-type-specific mechanobiological responses.
- The FDA approved a subcutaneous form of pembrolizumab in 2025, developed through ISS-based protein crystal growth research targeting the ADAR1 gene, while rebecsinib became the first space-tested cancer drug to enter clinical trials.
- The global microgravity pharmaceutical manufacturing market, valued at $1.5 billion in 2025, is projected to reach $9.8 billion by 2034, driven by commercial space stations and nano/microsatellites (CubeSats) that are becoming viable platforms for pharmaceutical experiments.
- The United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA), Civil Aviation Authority (CAA), and Regulatory Innovation Office have streamlined inter-agency regulatory processes in 2026 to support the development of a dedicated regulatory pathway for space-based pharmaceutical manufacturing.
Scientific Mechanisms: Why Microgravity Matters
Under normal Earth gravity, protein crystals and complex biologics form with gravitational sedimentation interference, resulting in structural irregularities. In microgravity, proteins and biologics form more slowly and uniformly, producing higher-quality crystal structures essential for accurate structure-based drug design. Additionally, microgravity alters cytoskeletal organisation, focal adhesion signalling, and extracellular matrix interactions in cancer cells — mechanisms directly relevant to understanding metastasis, invasion, and treatment resistance. Researchers have also found that microgravity affects spheroid (3D cell cluster) formation, which more closely resembles actual tumour architecture than traditional 2D cell culture, potentially improving the predictive value of drug screening experiments.
India’s Space Economy and ISRO’s Role
India’s space economy, valued at approximately $13 billion, ranks as the third-largest space-tech power globally and fifth among major government space agencies by budget. While ISRO has not yet developed dedicated space oncology infrastructure comparable to NASA’s ISS programmes, falling launch costs and the emergence of commercial platforms create opportunities for India to enter this field, particularly given India’s already-strong pharmaceutical manufacturing base — often termed the “pharmacy of the world.”
Regulatory Innovation as a Global Trend
The regulatory streamlining seen in the UK, where multiple regulatory bodies have harmonised “dual-regulation” hurdles that previously made space-based pharmacology commercially risky, represents an important governance innovation. This model — coordinated regulatory clearance across space, aviation, and medicines regulators — could serve as a template for India, where multiple ministries (Department of Space, Ministry of Health and Family Welfare, Central Drugs Standard Control Organisation) would need to coordinate to enable similar innovation domestically.
Economic and Public Health Implications for India
Given India’s dual position as both a major generic pharmaceutical manufacturer and a country facing an escalating cancer burden, space oncology offers a potential long-term pathway to indigenous advanced drug development capacity. If India can develop even modest space-based pharmaceutical manufacturing capabilities, it could reduce dependence on imported advanced biologics, lower manufacturing costs through microgravity-enabled reduced animal testing requirements, and position Indian pharmaceutical companies competitively in the emerging global space-manufacturing market projected to nearly grow sevenfold by 2034.
Challenges in Implementation
Significant barriers remain before space oncology can be operationalised at scale, including extremely high launch and orbital operation costs, the technical complexity of automating pharmaceutical manufacturing processes in orbit without human intervention, safety and quality assurance protocols for space-manufactured drugs re-entering Earth’s regulatory systems, and the absence of a harmonised international regulatory framework governing space-based pharmaceutical production and its terrestrial commercialisation.
Way Forward
India should consider establishing a dedicated space biotechnology research programme under ISRO, in partnership with premier cancer research institutions such as Tata Memorial Centre and All India Institute of Medical Sciences, to begin building indigenous expertise in microgravity oncology research. The Department of Biotechnology and Central Drugs Standard Control Organisation should proactively study international regulatory models, such as the UK’s streamlined dual-regulation approach, to prepare India’s own regulatory pathway well in advance of commercial space pharmaceutical manufacturing becoming viable. India should also leverage its cost-competitive space launch capabilities to position itself as an affordable partner for international space-based pharmaceutical research collaborations, converting its space economy advantage into a health-sector dividend.
Relevance for UPSC and SSC Examinations
This topic is highly relevant for UPSC GS Paper III (Science and Technology — space technology applications, biotechnology, health innovation) and can also connect with GS Paper II (health policy, regulatory governance). Key terms include microgravity, International Space Station (ISS), pembrolizumab, ADAR1 gene, CubeSats, focal adhesion, spheroid formation, and Medicines and Healthcare Products Regulatory Agency (MHRA). For SSC exams, this topic is relevant under Science and Technology current affairs, particularly regarding India’s space programme and health sector innovations.